Exagen (XGN) Capital Expenditures (2018 - 2026)

Exagen (XGN) has 9 years of Capital Expenditures data on file, last reported at $72000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 59.09% year-over-year to $72000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$896000.0 (down 937.38% YoY) and the FY2025 annual result came in at -$792000.0, down 1157.14% from the prior year.
• Capital Expenditures grew to $72000.0 in Q1 2026, from -$809000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $3.7 million in Q4 2022 to a low of -$886000.0 in Q2 2022.
• A 5-year average of $211823.5 and a median of $33000.0 in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2024 — Capital Expenditures tumbled 2780.0% — and 2025, when it soared 2833.33%.
• Tracing XGN's Capital Expenditures over 5 years: stood at $3.7 million in 2022, then slumped by 100.41% to -$15000.0 in 2023, then plunged by 2780.0% to -$432000.0 in 2024, then plunged by 87.27% to -$809000.0 in 2025, then surged by 108.9% to $72000.0 in 2026.
• The last three Capital Expenditures figures came in at $72000.0 (Q1 2026), -$809000.0 (Q4 2025), and -$305000.0 (Q3 2025), per Business Quant data.